Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta‐analysis
暂无分享,去创建一个
[1] R. Reiter,et al. Mechanisms of cancer inhibition by melatonin , 2004, Journal of pineal research.
[2] Vijayalaxmi,et al. Melatonin as a radioprotective agent: a review. , 2004, International journal of radiation oncology, biology, physics.
[3] B. Djulbegovic,et al. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group , 2004, BMJ : British Medical Journal.
[4] P. Lissoni,et al. Five years survival in metastatic non‐small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial , 2003, Journal of pineal research.
[5] Francine Laden,et al. Night-shift work and risk of colorectal cancer in the nurses' health study. , 2003, Journal of the National Cancer Institute.
[6] M. Vaghi,et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. , 2003, Anticancer research.
[7] A. Ardizzoia,et al. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients. , 2003, Neuro endocrinology letters.
[8] C. Gentile,et al. The chemistry of melatonin's interaction with reactive species , 2003, Journal of pineal research.
[9] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[10] Vijayalaxmi,et al. Melatonin: from basic research to cancer treatment clinics. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Lissoni. Is there a role for melatonin in supportive care? , 2002, Supportive Care in Cancer.
[12] D. Blask,et al. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. , 2002, Current topics in medicinal chemistry.
[13] R. Stevens,et al. Night shift work, light at night, and risk of breast cancer. , 2001, Journal of the National Cancer Institute.
[14] A. Morera,et al. Seguridad en el uso de la melatonina , 2001 .
[15] Douglas G Altman,et al. Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.
[16] M. de la Varga,et al. [Safety in melatonin use]. , 2001, Actas espanolas de psiquiatria.
[17] G. Maestroni,et al. Anti-angiogenic activity of melatonin in advanced cancer patients. , 2001, Neuro endocrinology letters.
[18] M. Mandalà,et al. Abrogation of the Negative Influence of Opioids on IL–2 Immunotherapy of Renal Cell Cancer by Melatonin , 2000, European Urology.
[19] S. Barni,et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. , 1999, European journal of cancer.
[20] D. Blask,et al. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. , 1999, Cancer research.
[21] H. Bartsch,et al. Melatonin in cancer patients and in tumor-bearing animals. , 1999, Advances in experimental medicine and biology.
[22] John Calvin Reed,et al. A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells. , 1998, British Journal of Cancer.
[23] P. Ghezzi,et al. Mechanism of the inhibitory effect of melatonin on tumor necrosis factor production in vivo and in vitro. , 1998, European journal of pharmacology.
[24] B. Guardiola‐Lemaître. Toxicology of Melatonin , 1997, Journal of biological rhythms.
[25] W. Richardson,et al. Selecting and Appraising Studies for a Systematic Review , 1997, Annals of Internal Medicine.
[26] P. Lissoni,et al. Melatonin as a new possible anti-inflammatory agent. , 1997, Journal of biological regulators and homeostatic agents.
[27] S. Barni,et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first‐line treatment of advanced non‐small cell lung cancer patients in a poor clinical state , 1997, Journal of pineal research.
[28] A. Brzezinski. Melatonin in humans. , 1997, The New England journal of medicine.
[29] S. Barni,et al. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma , 1996, Journal of pineal research.
[30] S. Barni,et al. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. , 1996, British Journal of Cancer.
[31] S. Barni,et al. Is there a role for melatonin in the treatment of neoplastic cachexia? , 1996, European journal of cancer.
[32] S. Barni,et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. , 1996, Oncology.
[33] S. Barni,et al. A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients. , 1995, Oncology reports.
[34] C H Schmid,et al. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. , 1995, Journal of clinical epidemiology.
[35] S. Barni,et al. A Randomized Study of Immunotherapy with Low-Dose Subcutaneous Interleukin-2 plus Melatonin Vs Chemotherapy with Cisplatin and Etoposide as First-Line Therapy for Advanced Non-Small Cell Lung Cancer , 1994, Tumori.
[36] S. Barni,et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms , 1994, Cancer.
[37] S. Barni,et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. , 1994, British Journal of Cancer.
[38] K. Bichler,et al. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. , 1992, Clinica chimica acta; international journal of clinical chemistry.
[39] S. Barni,et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. , 1992, Oncology.